Suppr超能文献

肾移植患者从环孢素A治疗转换为传统治疗后的移植物排斥反应

[Graft rejection after changing from cyclosporin A therapy to conventional treatment in kidney transplant patients].

作者信息

Matl I, Gintelová J, Jirka J, Rossmann P

机构信息

Klinika nefrologie Institutu klinické a experimentální medicíny, Praha.

出版信息

Cas Lek Cesk. 1993 May 18;132(10):301-4.

PMID:8513465
Abstract

Hundred and twenty live patients after the first transplantation of the kidney from a decreased donor with satisfactory graft function, treated with cyclosporine A combined with prednisone or combined with prednisone or combined with prednisone and azathioprine were divided into three groups: A--20 patients changed during the 6th-9th month after transplantation to conventional azathioprine-prednisone treatment. B--68 patients switched to this treatment during the 10h-15th month following transplantation. K--37 patients who were not switched to other treatment during the mentioned period. Within 3 months after the switched rejection develop in 21% of the patients in group A and 20% patients in group B. The incidence of rejections during a comparable period in group K was significantly lower (3%), as compared with group A and insignificantly lower (14%), as compared with group B. The majority of rejections was documented by biopsy but no morphological difference was found between rejections which developed in patients switched and not switched to other treatment. It was striking that there was a difference, though insignificant, in the sensitivity of rejections to antirejection treatment with methylprednisolone after switch to a different preparation: in group A 25%, in group B 37% and in group K 80%. Patients in group A with rejection after the switch had developed a rejection even before the switch significantly more frequently (in 75%) than in group B (in 7%) and these rejections led significantly more frequently to loss of the graft.

摘要

120例首次接受来自脑死亡供者肾脏移植且移植肾功能良好的存活患者,接受环孢素A联合泼尼松治疗,或联合泼尼松治疗,或联合泼尼松和硫唑嘌呤治疗,被分为三组:A组——20例患者在移植后第6至9个月改为常规硫唑嘌呤-泼尼松治疗。B组——68例患者在移植后第10至15个月改为这种治疗。K组——37例患者在上述期间未改为其他治疗。在改为其他治疗后的3个月内,A组21%的患者和B组20%的患者发生排斥反应。与A组相比,K组在可比期间的排斥反应发生率显著较低(3%),与B组相比略低(14%)。大多数排斥反应通过活检记录,但在改为其他治疗和未改为其他治疗的患者中发生的排斥反应之间未发现形态学差异。令人惊讶的是,改为不同制剂后,排斥反应对甲泼尼龙抗排斥治疗的敏感性存在差异,尽管不显著:A组为25%,B组为37%,K组为80%。A组改为其他治疗后发生排斥反应的患者,在改为其他治疗之前发生排斥反应的频率显著高于B组(75%对7%),并且这些排斥反应导致移植肾丧失的频率显著更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验